...
首页> 外文期刊>American Journal of Pathology: Official Publication of the American Association of Pathologists >A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.
【24h】

A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.

机译:大鼠胰岛素抵抗和非酒精性脂肪性肝炎的模型:过氧化物酶体增殖物激活受体-α和n-3多不饱和脂肪酸治疗肝损伤的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Insulin resistance induces nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH). We used a high-fat, high-calorie solid diet (HFD) to create a model of insulin resistance and NASH in nongenetically modified rats and to study the relationship between visceral adipose tissue and liver. Obesity and insulin resistance occurred in HFD rats, accompanied by a progressive increase in visceral adipose tissue tumor necrosis factor (TNF)-alpha mRNA and in circulating free fatty acids. HFD also decreased adiponectin mRNA and peroxisome proliferator-activated receptor (PPAR)-alpha expression in the visceral adipose tissue and the liver, respectively, and induced hepatic insulin resistance through TNF-alpha-mediated c-Jun N-terminal kinase (JNK)-dependent insulin receptor substrate-1Ser307 phosphorylation. These modifications lead to hepatic steatosis accompanied by oxidative stress phenomena, necroinflammation, and hepatocyte apoptosis at 4 weeks and by pericentral fibrosis at 6 months. Supplementation of n-3 polyunsaturated fatty acid, a PPARalpha ligand, to HFD-treated animals restored hepatic adiponectin and PPARalpha expression, reduced TNF-alpha hepatic levels, and ameliorated fatty liver and the degree of liver injury. Thus, our model mimics the most common features of NASH in humans and provides an ideal tool to study the role of individual pathogenetic events (as for PPARalpha down-regulation) and to define any future experimental therapy, such as n-3 polyunsaturated fatty acid, which ameliorated the degree of liver injury.
机译:胰岛素抵抗可诱发非酒精性脂肪肝疾病和非酒精性脂肪性肝炎(NASH)。我们使用高脂肪,高热量的固体饮食(HFD)在非转基因大鼠中创建胰岛素抵抗和NASH模型,并研究内脏脂肪组织与肝脏之间的关系。肥胖和胰岛素抵抗发生在HFD大鼠中,并伴随着内脏脂肪组织肿瘤坏死因子(TNF)-αmRNA和循环游离脂肪酸的逐渐增加。 HFD还分别降低内脏脂肪组织和肝脏中的脂联素mRNA和过氧化物酶体增殖物激活受体(PPAR)-α表达,并通过TNF-α介导的c-Jun N-末端激酶(JNK)-诱导肝胰岛素抵抗依赖性胰岛素受体底物-1Ser307磷酸化。这些修饰导致肝脂肪变性,并伴有氧化应激现象,坏死性炎症和第4周的肝细胞凋亡,以及第6个月的中心周围纤维化。向HFD治疗的动物补充n-3多不饱和脂肪酸(一种PPARalpha配体)可恢复肝脂联素和PPARalpha的表达,降低TNF-alpha肝水平,并改善脂肪肝和肝损伤的程度。因此,我们的模型模仿了人类NASH的最常见特征,并提供了一个理想的工具来研究个体致病事件的作用(如PPARα下调)并定义任何未来的实验疗法,例如n-3多不饱和脂肪酸,改善了肝损伤的程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号